Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-Specific Chimeric Antigen Receptor-Positive T Cells in Patients With Metastatic Mesothelin-Expressing Breast Cancer

NCT02792114 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT02792114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02792114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-Specific Chimeric Antigen Receptor-Positive T Cells in Patients With Metastatic Mesothelin-Expressing Breast Cancer
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 30, 2016
Completion date
June 30, 2027
Enrollment
186 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastatic her2-negative breast